Dexcom climbs after plans to revamp board panel with Elliott, bring 2 directors

DexCom

15/05/2026 10:26

** Shares of Dexcom DXCM.O rise 3.7% at $59.99 premarket

** The medical device maker on Thursday said it agreed to collaborate with Elliott Investment Management, among its largest investors, to identify two new independent board members

** CEO Jake Leach said on an investor call that DXCM is focusing on refreshing its board and seeks to add independent directors with medtech and operations expertise

** With the additions, the board would have appointed six new independent directors since the beginning of 2023 - DXCM

** Adds that the existing Technology Committee on the board will now become the Operations and Innovation Committee

** As of last close, DXCM stock down 12.88% YTD

 (Reporting by Tharuniyaa Lakshmi in Bengaluru)

 ((tharuniyaa@thomsonreuters.com))